Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| IF# 1358648 | |||
| 1R34MH100276-01 | U.S. NIH Grant/Contract | View source | |
| GCO 11-1555 | Other Identifier | Icahn School of Medicine at Mount Sinai | |
| R34MH100276 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute of Mental Health (NIMH) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to pilot the use of Insulin-Like Growth Factor-1 (IGF-1) treatment in 22q13 Deletion Syndrome (Phelan-McDermid Syndrome) caused by SHANK3 gene deficiency in order to evaluate safety, tolerability, and efficacy. IGF-1 is an injection under the skin that contains human IGF-1. IGF-1 is approved by the FDA under the brand name Increlex for the treatment of children with short stature due to primary IGF-1 deficiency. It is being used off-label in the current study and is not FDA approved, nor has it yet been studied in humans for the treatment of SHANK3 deficiency.
Overall, there will be 1-3 screening visits, a baseline visit where study drug will first be administered, and then 10 follow-up visits. Follow-up visits will occur at week 2, week 4, week 8, and week 12 in each treatment phase (IGF-1 or placebo), and then again 4 weeks after study completion, Parents/guardians will be asked to administer the IGF-1/ placebo by injection at home and will also be responsible for monitoring glucose levels in the child. Parents/guardians will be trained in these methods, and will have scheduled phone calls and appointments where the dose and tolerability will be discussed.
Assessments include the following:
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Insulin-Like Growth Factor-1 (IGF-1) | Experimental | Injection |
|
| Normal saline | Placebo Comparator | Injection |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Insulin-Like Growth Factor-1 (IGF-1) | Drug | IGF-1 and placebo will each be administered for 3 months with a four-week washout period in between. IGF-1 will be administered for 3 months subcutaneously. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Aberrant Behavior Checklist - Social Withdrawal (ABC-SW) Subscale - Study 1 | 16 items on ABC-SW subscale, Each item is scored as 0 (never a problem), 1 (slight problem), 2 (moderately serious problem), or 3 (severe problem). Total score from 0 to 48 with higher score indicating poorer health outcomes. | Baseline and Week 12 |
| Change in Aberrant Behavior Checklist - Social Withdrawal (ABC-SW) Subscale Study 2 | 16 items on ABC-SW subscale, Each item is scored as 0 (never a problem), 1 (slight problem), 2 (moderately serious problem), or 3 (severe problem). Total score from 0 to 48 with higher score indicating poorer health outcomes.. | Baseline and Week 12 |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Repetitive Behavior Scale - Study 2 | Repetitive Behavior Scale (RBS) - Total Score 43 items, each item scored on 4-point scale: 0-Behavior does not occur, 1-Behavior occurs and is a mild problem, 2-Behavior occurs and is a moderate problem, 3-Behavior occurs and is a severe problem. with total score from 0 (mild) to 129 (severe). The subscales are stereotyped behaviors 6 items (subscale 0-18), self-injurious behaviors 8 items (subscale 0-24), Compulsive behaviors- 8 items (subscale 0-24), Ritualistic Behaviors 6 items (subscale from 0-18), Sameness 11 items (subscale 0-33), restricted behaviors 4 items (subscale 0-12). Total score is the sum of all items in the subscale with total score range from 0 to 129. Higher scores indicate greater symptom severity. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Alexander Kolevzon, MD | Icahn School of Medicine at Mount Sinai | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Seaver Austin Center, Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 25685306 | Result | Kolevzon A, Bush L, Wang AT, Halpern D, Frank Y, Grodberg D, Rapaport R, Tavassoli T, Chaplin W, Soorya L, Buxbaum JD. A pilot controlled trial of insulin-like growth factor-1 in children with Phelan-McDermid syndrome. Mol Autism. 2014 Dec 12;5(1):54. doi: 10.1186/2040-2392-5-54. eCollection 2014. | |
| 35395866 | Derived | Kolevzon A, Breen MS, Siper PM, Halpern D, Frank Y, Rieger H, Weismann J, Trelles MP, Lerman B, Rapaport R, Buxbaum JD. Clinical trial of insulin-like growth factor-1 in Phelan-McDermid syndrome. Mol Autism. 2022 Apr 8;13(1):17. doi: 10.1186/s13229-022-00493-7. |
| Label | URL |
|---|---|
| SHANK3 gene | View source |
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Study 1: Insulin-Like Growth Factor-1 (IGF-1) Then Normal Saline | Insulin-Like Growth Factor-1 (IGF-1) and then placebo administered for 3 months with a four-week washout period in between. IGF-1 will be administered for 3 months subcutaneously. |
| FG001 | Study 1: Normal Saline Then IGF-1 | 12 weeks in each treatment arm (placebo and then IGF-1), separated by a 4-week wash-out phase |
| FG002 | Study 2: Insulin-Like Growth Factor-1 (IGF-1) Then Normal Saline | Insulin-Like Growth Factor-1 (IGF-1) and then placebo administered for 3 months with a four-week washout period in between. IGF-1 will be administered for 3 months subcutaneously. |
| FG003 | Study 2: Normal Saline Then IGF-1 | 12 weeks in each treatment arm (placebo and then IGF-1), separated by a 4-week wash-out phase |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Period 1: 12 Weeks |
| |||||||||||||
| Washout 4 Weeks |
| |||||||||||||
| Period 2: 12 Weeks |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Study 1: Insulin-Like Growth Factor-1 (IGF-1) Then Normal Saline | Insulin-Like Growth Factor-1 (IGF-1) and then placebo administered for 3 months with a four-week washout period in between. IGF-1 will be administered for 3 months subcutaneously. |
| BG001 | Study 1: Normal Saline Then IGF-1 |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change in Aberrant Behavior Checklist - Social Withdrawal (ABC-SW) Subscale - Study 1 | 16 items on ABC-SW subscale, Each item is scored as 0 (never a problem), 1 (slight problem), 2 (moderately serious problem), or 3 (severe problem). Total score from 0 to 48 with higher score indicating poorer health outcomes. | Posted | Mean | Standard Error | score on a scale | Baseline and Week 12 |
|
28 weeks
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Insulin-Like Growth Factor-1 (IGF-1) | IGF-1 is an aqueous solution for injection containing human insulin-like growth factor-1 (Increlex; Ipsen Biopharmaceuticals, Inc)) produced by recombinant DNA technology. Dose titration was initiated at 0.04 mg/kg twice daily by subcutaneous injection, and increased, as tolerated, every week by 0.04 mg/kg per dose to a maximum of 0.12 mg/kg twice daily. Medication was administered subcutaneously twice daily with meals and glucose monitoring was performed by parents prior to each injection and at bedtime. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Constipation | Gastrointestinal disorders | Systematic Assessment |
The small sample size and expectancy bias due to relying on parent reported outcome measures may contribute to limitations in interpreting results.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Alexander Kolevzon, MD | Icahn School of Medicine at Mount Sinai | (212) 659-9134 | alexander.kolevzon@mssm.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Jan 1, 2013 | Jan 28, 2022 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| C536801 | Telomeric 22q13 Monosomy Syndrome |
| D001321 | Autistic Disorder |
| ID | Term |
|---|---|
| D000067877 | Autism Spectrum Disorder |
| D002659 | Child Development Disorders, Pervasive |
| D065886 | Neurodevelopmental Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D007334 | Insulin-Like Growth Factor I |
| C000604197 | mecasermin |
| D000077330 | Saline Solution |
| ID | Term |
|---|---|
| D013002 | Somatomedins |
| D000096764 | Insulin-Like Peptides |
| D036341 | Intercellular Signaling Peptides and Proteins |
| D010455 | Peptides |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Normal saline | Drug | Saline solution will be administered for three months subcutaneously. |
|
|
| Baseline and Week 12 |
| Change in CGI-Improvement and Severity Scales; - Study 2 | The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. The Clinical Global Impression - Improvement scale (CGI-I) is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. and rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. | Baseline and Week 12 |
| Change in Caregiver Strain Questionnaire | 21 question tool, about caregiver strain, where each question uses a Likert scale where 1 is "Not at all" and 5 is "Very much." The full scale ranges from 21-105, where higher scores indicate more severe strain. | Baseline and Week 12 |
| Change in Sensory Profile (SP) - Study 2 | The SP is a standardized parent-completed questionnaire that assesses sensory processing and its impact on the functioning of children ages 3-10 yr. The 125 items represent behaviors that can be interpreted as responses to sensory experiences. The parent rates the observed frequency of these behaviors on a 5-point Likert scale (ranging from 1 always to 5 never). The tool consists of 14 sections, listed below, that refer to sensory processing, modulation, and behavioral and emotional responses. Subscale scores are listed below. Each section's raw score is compared with a threshold value to determine a category of performance: typical performance, probable difference (1 standard deviation below the mean), and definite difference (2 standard deviations below the mean). A lower raw score means a greater difference. | Baseline and Week 12 |
| Change in Short Sensory Profile (SSP) - Study 2 | The Short Sensory Profile is a caregiver report measure consisting of 38 items, each scored on a 1-point (always) to 5-point (never) Likert scale. SSP Subscales Tactile Sensitivity (7 to 35) Taste/Smell Sensitivity (4 to 20), Movement Sensitivity (3 to 15), Under-Responsive/Seek Sensation (7 to 35) , Auditory Filtering (6 to 30), Low Energy/Weak (6 to 30), Visual/Auditory Sensitivity (5 to 25), with total scale from (38 to 190) Lower scores indicate more sensory alterations. | Baseline and 12 weeks |
| Phelan-McDermid Syndrome Foundation | View source |
| COMPLETED |
|
| NOT COMPLETED |
|
| COMPLETED |
|
| NOT COMPLETED |
|
|
12 weeks in each treatment arm (placebo and then IGF-1), separated by a 4-week wash-out phase |
| BG002 | Study 2: Insulin-Like Growth Factor-1 (IGF-1) Then Normal Saline | Participants who have pathogenic deletions or sequence variants of the SHANK3 gene. Insulin-Like Growth Factor-1 (IGF-1) and then placebo administered for 3 months with a four-week washout period in between. IGF-1 will be administered for 3 months subcutaneously. |
| BG003 | Study 2: Normal Saline Then IGF-1 | 12 weeks in each treatment arm (placebo and then IGF-1), separated by a 4-week wash-out phase |
| BG004 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| ABC-SW subscale score | 16 items on ABC-SW subscale, Each item is scored as 0 (never a problem), 1 (slight problem), 2 (moderately serious problem), or 3 (severe problem). Total score from 0 to 48 with higher score indicating poorer health outcomes. | Mean | Standard Deviation | units on a scale |
|
| Repetitive Behavior Scale (RBS) - Total | Total Score 43 items, each item scored on 4-point scale: 0-3, with total score from 0 (mild) to 129 (severe). The subscales are stereotyped behaviors 6 items (subscale 0-18), self-injurious behaviors 8 items (subscale 0-24), Compulsive behaviors- 8 items (subscale 0-24), Ritualistic Behaviors 6 items (subscale from 0-18), Sameness 11 items (subscale 0-33), restricted behaviors 4 items (subscale 0-12). Total score is the sum of all items in the subscale with total score range from 0 to 129. Higher scores indicate greater symptom severity. | Mean | Standard Deviation | units on a scale |
|
| Vineland Adaptive Behavior Composite Standard Score | Standardized scores on the Adaptive behavior composite range from 20-160 with higher scores indicating better functioning. | Mean | Standard Deviation | units on a scale |
|
| Study 1: Normal Saline |
Placebo consisted of saline prepared in identical bottles by the research pharmacy at Mount Sinai. |
|
|
| Primary | Change in Aberrant Behavior Checklist - Social Withdrawal (ABC-SW) Subscale Study 2 | 16 items on ABC-SW subscale, Each item is scored as 0 (never a problem), 1 (slight problem), 2 (moderately serious problem), or 3 (severe problem). Total score from 0 to 48 with higher score indicating poorer health outcomes.. | Posted | Mean | Standard Deviation | score on a scale | Baseline and Week 12 |
|
|
|
| Secondary | Change in Repetitive Behavior Scale - Study 2 | Repetitive Behavior Scale (RBS) - Total Score 43 items, each item scored on 4-point scale: 0-Behavior does not occur, 1-Behavior occurs and is a mild problem, 2-Behavior occurs and is a moderate problem, 3-Behavior occurs and is a severe problem. with total score from 0 (mild) to 129 (severe). The subscales are stereotyped behaviors 6 items (subscale 0-18), self-injurious behaviors 8 items (subscale 0-24), Compulsive behaviors- 8 items (subscale 0-24), Ritualistic Behaviors 6 items (subscale from 0-18), Sameness 11 items (subscale 0-33), restricted behaviors 4 items (subscale 0-12). Total score is the sum of all items in the subscale with total score range from 0 to 129. Higher scores indicate greater symptom severity. | Participants in Study 2 | Posted | Mean | Standard Deviation | score on a scale | Baseline and Week 12 |
|
|
|
| Secondary | Change in CGI-Improvement and Severity Scales; - Study 2 | The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. The Clinical Global Impression - Improvement scale (CGI-I) is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. and rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. | Posted | Mean | Standard Deviation | score on a scale | Baseline and Week 12 |
|
|
|
| Secondary | Change in Caregiver Strain Questionnaire | 21 question tool, about caregiver strain, where each question uses a Likert scale where 1 is "Not at all" and 5 is "Very much." The full scale ranges from 21-105, where higher scores indicate more severe strain. | 4 participants missing data from at least one data point | Posted | Mean | Standard Deviation | score on a scale | Baseline and Week 12 |
|
|
|
| Secondary | Change in Sensory Profile (SP) - Study 2 | The SP is a standardized parent-completed questionnaire that assesses sensory processing and its impact on the functioning of children ages 3-10 yr. The 125 items represent behaviors that can be interpreted as responses to sensory experiences. The parent rates the observed frequency of these behaviors on a 5-point Likert scale (ranging from 1 always to 5 never). The tool consists of 14 sections, listed below, that refer to sensory processing, modulation, and behavioral and emotional responses. Subscale scores are listed below. Each section's raw score is compared with a threshold value to determine a category of performance: typical performance, probable difference (1 standard deviation below the mean), and definite difference (2 standard deviations below the mean). A lower raw score means a greater difference. | Posted | Mean | Standard Deviation | units on a scale | Baseline and Week 12 |
|
|
|
| Secondary | Change in Short Sensory Profile (SSP) - Study 2 | The Short Sensory Profile is a caregiver report measure consisting of 38 items, each scored on a 1-point (always) to 5-point (never) Likert scale. SSP Subscales Tactile Sensitivity (7 to 35) Taste/Smell Sensitivity (4 to 20), Movement Sensitivity (3 to 15), Under-Responsive/Seek Sensation (7 to 35) , Auditory Filtering (6 to 30), Low Energy/Weak (6 to 30), Visual/Auditory Sensitivity (5 to 25), with total scale from (38 to 190) Lower scores indicate more sensory alterations. | Posted | Mean | Standard Deviation | score on a scale | Baseline and 12 weeks |
|
|
|
| 0 |
| 19 |
| 0 |
| 19 |
| 19 |
| 19 |
| EG001 | Normal Saline | Placebo | 0 | 19 | 0 | 19 | 19 | 19 |
| Sedation | Nervous system disorders | Systematic Assessment |
|
| Decreased appetite | Metabolism and nutrition disorders | Systematic Assessment |
|
| Periobital/facial swelling | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Diarrhea | Gastrointestinal disorders | Systematic Assessment |
|
| URTI | Infections and infestations | Systematic Assessment |
|
| Sleep Disturbance | Nervous system disorders | Systematic Assessment |
|
| Increased appetite | Metabolism and nutrition disorders | Systematic Assessment |
|
| Mood changes/irritability | Nervous system disorders | Systematic Assessment |
|
| Increased thirst | Metabolism and nutrition disorders | Systematic Assessment |
|
| Increased phlegm | Infections and infestations | Systematic Assessment |
|
| Teeth grinding | Nervous system disorders | Systematic Assessment |
|
| Cough | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Hand flapping | Nervous system disorders | Systematic Assessment |
|
| Increased bowel movements | Gastrointestinal disorders | Systematic Assessment |
|
| Increased chewing/biting | Nervous system disorders | Systematic Assessment |
|
| Decreased visual acuity | Eye disorders | Systematic Assessment |
|
| Lethargy/decreased energy | Nervous system disorders | Systematic Assessment |
|
| Cooler body temperature/sweating | Nervous system disorders | Systematic Assessment |
|
| Runny nose/congestion | Infections and infestations | Systematic Assessment |
|
| Gait changes/fell | Nervous system disorders | Systematic Assessment |
|
| Stomach virus | Infections and infestations | Systematic Assessment |
|
| Anxiety | Nervous system disorders | Systematic Assessment |
|
| Increased urine frequency | Renal and urinary disorders | Systematic Assessment |
|
| Fever | Infections and infestations | Systematic Assessment |
|
| Increased energy | Nervous system disorders | Systematic Assessment |
|
| Gagging | Gastrointestinal disorders | Systematic Assessment |
|
| Conjunctivitis | Infections and infestations | Systematic Assessment |
|
| Erythema/swollen eyes | Eye disorders | Systematic Assessment |
|
| Vomiting | Gastrointestinal disorders | Systematic Assessment |
|
| Rash | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Facial swelling | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Warmer body temperature | Endocrine disorders | Systematic Assessment |
|
| Hair loss | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Increased aggression | Nervous system disorders | Systematic Assessment |
|
| Hypoglycemia | Endocrine disorders | Systematic Assessment |
|
| Stomach aches | Gastrointestinal disorders | Systematic Assessment |
|
| Urinary Tract Infection | Infections and infestations | Systematic Assessment |
|
| Bruising at injection site | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Breast buds developed | Reproductive system and breast disorders | Systematic Assessment |
|
| Bloody nose | Blood and lymphatic system disorders | Systematic Assessment |
|
| Elevated heart rate | Cardiac disorders | Systematic Assessment |
|
| Increased ear wax | Ear and labyrinth disorders | Systematic Assessment |
|
| Increased reflux | Gastrointestinal disorders | Systematic Assessment |
|
| Ear Infections | Infections and infestations | Systematic Assessment |
|
| Broken bone | Injury, poisoning and procedural complications | Systematic Assessment |
|
| Increased drooling | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Systematic Assessment |
|
| Increased eye rolling | Nervous system disorders | Systematic Assessment |
|
| Seizure | Nervous system disorders | Systematic Assessment |
|
| Redness around perineum | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
Not provided
Not provided
Not provided
| D000602 | Amino Acids, Peptides, and Proteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D001685 | Biological Factors |
| D000077324 | Crystalloid Solutions |
| D007552 | Isotonic Solutions |
| D012996 | Solutions |
| D004364 | Pharmaceutical Preparations |
| RBS-Compulsive Behavior |
|
| RBS-Sameness Behavior |
|
| RBS-Restricted Behavior |
|
| RBS-Total |
|
| Week 12 |
|
| SP-Vestibular Processing (subscale range 11-55) |
|
| SP-Touch Processing (subscale range 18-90) |
|
| SP-Multisensory Processing (subscale range 7-35) |
|
| SP-Oral Sensory Processing (subscale range 12-60) |
|
| SP-Sensory Processing Related to Endurance/Tone (subscale range 9-45) |
|
| SP-Modulation Related to Body Position and Movement (subscale range 10-50) |
|
| SP-Modulation of Movement Affecting Activity Level (subscale range 7-35) |
|
| SP-Modulation of Sensory Input Affecting Emotional Responses (subscale range 4-20) |
|
| SP-Modulation of Visual Input Affecting Emotional Responses & Activity Level (subscale range 4-20) |
|
| SP-Emotional/Social Responses (subscale range 17-85) |
|
| SP-Behavioral Outcomes of Sensory Processing (subscale range 6-30) |
|
| SP-Items Indicating Thresholds for Response (subscale range 3-15) |
|
| SSP-Movement Sensitivity |
|
| SSP-Underresponsive/Seeks Sensation |
|
| SSP-Auditory Filtering |
|
| SSP-Low Energy/Weak |
|
| SSP-Visual/Auditory Sensitivity |
|
| SSP-Total |
|